RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival.
RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival.
复制标题
RECK 表达与肝细胞癌中的血管生成和免疫原性肿瘤微环境相关,并且是更好生存的预后因素
DOI:
10.7150/jca.56167
复制
发表时间:
2021
影响因子:
3.9
通讯作者:
Li T
中科院分区:
文献类型:
--
作者:
Dong ZR;Chen ZQ;Yang XY;Ding ZN;Liu KX;Yan LJ;Meng GX;Yang YF;Yan YC;Yao SY;Yang CC;Zhi XT;Li T
Angiogenesis and immunosuppression have been described as closely related processes that can occur in parallel. As an inhibitor of matrix metalloproteinase, whether the level of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) in hepatocellular carcinoma (HCC) reflects a link between angiogenesis and immunosuppression is still unknown. We analyzed RNA expression, immune infiltration and survival of HCC from The Cancer Genome Atlas databases. Immune scores and stromal scores were calculated based on the ESTIMATE algorithm to quantify the immune and stromal components in HCC. The association between RECK and clinicopathological features was further investigated by immunohistochemistry on tissue microarray. We found that the prognosis of patients with high RECK expression was significantly better than that of patients with low RECK expression. High RECK expression was associated with high ESTIMATE Score, recruitment of more tumor-infiltrating lymphocytes, low tumor purity, and high PD-L1 expression. In addition, positive RECK expression was associated with a lower incidence of vascular invasion and recurrence, a lower level of alpha fetoprotein (AFP) and microvessel density and a better tumor differentiation. Multivariate analyses revealed that reduced RECK expression was an independent prognostic factor for recurrence and poor prognosis. In conclusion, high RECK expression reflects an immunogenic and hypovascularity status in HCC. RECK is a promising prognostic marker for survival of HCC and may act as a complementary indicator for patients to receive anti-angiogenic therapy or immunotherapy.
登录
查看更多内容
DOI:
10.1111/liv.13697
发表时间:
2018-08
期刊:
Liver international : official journal of the International Association for the Study of the Liver
影响因子:
--
作者:
Chang B;Shen L;Wang K;Jin J;Huang T;Chen Q;Li W;Wu P
通讯作者:
Wu P
影响因子:
10.9
作者:
Brown ZJ;Heinrich B;Steinberg SM;Yu SJ;Greten TF
通讯作者:
Greten TF
影响因子:
6.2
作者:
Clark, Jonathan C. M.;Akiyama, Toru;Choong, Peter F. M.
通讯作者:
Choong, Peter F. M.
影响因子:
4.6
作者:
Ruiz-Gomez, Gloria;Vogel, Sarah;Hempel, Ute
通讯作者:
Hempel, Ute
影响因子:
13.5
作者:
Calderaro, Julien;Rousseau, Benoit;Pawlotsky, Jean-Michel
通讯作者:
Pawlotsky, Jean-Michel